Integrating Genetic and Immune Profiles for Personalized Immunotherapy in Alzheimer’s Disease

Alzheimer's disease is the leading cause of dementia worldwide, with the number of patients expected to reach 131 million by 2050. Current treatments can only alleviate the symptoms of AD and are unable to halt the progression of the disease. Personalized immunotherapy shows great potential, as it can improve treatment efficacy and reduce side effects through precise targeting and early intervention. This paper emphasizes the importance of integrating genetic background with immune status, reviews the genetic and immune characteristics of AD, discusses multi-omics data integration methods, biomarker identification, patient stratification, and precision treatment strategies, as well as the current status and prospects of immunotherapy applications, thereby providing new directions for future AD treatments.